The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2012

Conditions
Metabolic Bone Disease
Interventions
DRUG

Lanthanum Carbonate (Fosrenol)

Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner

DRUG

placebo

Initial dose of placebo will be 1 pill three times a day

Trial Locations (1)

60201

NorthShore University HealthSystem, Evanston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Endeavor Health

OTHER